Oidtman, Rachel J.
Meleleo, Giulio
Sharomi, Oluwaseun
Matthews, Ian R.
Ntais, Dionysios
Nachbar, Robert B.
Malik, Tufail M.
Bakker, Kevin M.
Funding for this research was provided by:
Merck
Article History
Received: 16 October 2024
Accepted: 24 January 2025
First Online: 11 February 2025
Declarations
:
: RO, OS, TM, and KB are full-time employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. IM and DN are full-time employees of MSD (UK) Ltd, London, United Kingdom and may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. GM and RN are consultants whose institution (Wolfram Research, Inc., Champaign IL, USA) is paid by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. RN may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. V116 was developed by Merck & Co., Inc., Rahway, NJ, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: This article does not contain any new studies with human participants or animals performed by any of the authors.